Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus gemcitabine for second-line advanced esophageal cancer
ChiCTR1800020199Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and gemcitabine in esophageal cancer, sponsored by Chinese PLA General Hospital. Primary endpoints: overall survival, progression-free survival and 2 more. Started Jan 2019; status: recruiting.
02
Drugs
anlotinibgemcitabine
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR1800020199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020199.